Asset profile

Niraparib

Small molecule

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. No upcoming registrational readout date is posted to the registry — check News for topline announcements.

How the evidence outlook works ↗

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
December 2026 (1)
Phase 2Ovarian Neoplasms, Breast NeoplasmsRecruiting
Est. primary completion 2026-12-28 · NCT04641247 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (4)
February 2027 (1)
Phase 2Breast Cancer, Triple Negative Breast CancerActive not recruiting
Est. primary completion 2027-02-01 · NCT04837209 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2027-09 · NCT05519670 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 1/2Metastatic Breast Cancer, HER2 Positive Breast CarcinomaActive not recruiting
Est. primary completion 2027-11-01 · NCT03368729 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.